Guest: Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antim

Host: Joyce O'Shaughnessy, MD Hormone receptor-positive, HER2-negative cancer is the most common subtype of breast cancer. Initial treatment consists of surgery with or without radiotherapy or chemoradiotherapy, followed by adjuvant endocri

Host: Martha Kingman, DNP, FNP-C Guest: Susanne McDevitt, DNP, ACNP-BC This program focuses on early symptom identification and timely diagnosis in patients with pulmonary hypertension (PH). Learn how appropriate risk stratification can faci

Guest: C. Brendan Montano, MD Guest: Anton P. Porsteinsson, MD Early diagnosis and management of agitation in Alzheimers disease (AAD) is part of a comprehensive treatment plan. How can you help caregivers recognize subtle signs of AAD to f

Host: Jean M. Elwing, MD Host: Nicholas Kolaitis, MD, MAS Guest: Katharine Clapham, MD Pulmonary Arterial Hypertension (PAH) requires a personalized, multidisciplinary approach, which is often lacking in remote regions due to limited acc

Host: Denis Hadjiliadis, MD, MHS, PhD Guest: Gregory S. Sawicki, MD, MPH Guest: Alexandra Wilson, MS, RDN, CDE Guest: Susanna A. McColley, MD Cystic Fibrosis (CF) care faces challenges from health disparities, limited access, and uni

Guest: Eric D. Austin, MD, MSCI Guest: Hilary M. DuBrock, MD Guest: H. James Ford, MD Guest: Gustavo A. Heresi, MD, MS Guest: Gergely Meszaros, JD, MSc Guest: Oksana A. Shlobin, MD Guest: Ioana Preston, MD Guest: Lucilla Piccar

Host: Farrukh Abbas, MD Guest: Megan Conroy, MD, MA(Ed) Listen in as Farrukh Abbas, MD, FCCP, and Megan Conroy, MD, MAEd, FCCP, discuss the role of the care team in COPD diagnosis, recent changes in classifications and updates to the GOLD gu

Host: David H. Ilson, MD, PhD Guest: Sunnie Kim, MD This educational activity delves into biomarker-driven strategies for first-line therapy in metastatic gastric and gastroesophageal junction (GEJ) cancers. Participants will explore the lat

Guest: Gilberto de Lima Lopes, Jr, MD, MBA, FASCO Guest: Jyoti Patel, MD The MET pathway can be activated by MET exon 14 skipping mutations, gene amplification, or overexpression. Mutations within this pathway carry a poor prognosis for pati